Agilon Health (AGL) AI Stock Analysis

• Market Cap: $902.41M
• Dividend Yield: N/A
• Average Volume (3M): 4.04M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: 19.18%
• EPS Growth: -6.14%
• Country: US
• Employees: 1,076
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Care Facilities
• EPS (TTM): 0.03
• Shares Outstanding: 413,951,780
• 10 Day Avg. Volume: 3,327,832
• 30 Day Avg. Volume: 4,038,667
• PEG Ratio: 0.83
• Price to Book (P/B): 6.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -40.30
• Enterprise Value/Market Cap: 6.80
• Enterprise Value/Revenue: 0.27
• Enterprise Value/Gross Profit: -192.13
• Enterprise Value/Ebitda: -6.50
• 1Y Price Target: $4.60
• Price Target Upside: 99.13% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 13

• Rating: 44 Neutral
• Price Target: $2.00 ▼(-13.42%Downside)

Agilon Health's overall stock score reflects significant financial and valuation challenges, with ongoing profitability and cash flow issues being the most pressing concerns. Although there are advancements in technology and stable membership, weak technical indicators and a negative earnings outlook weigh heavily on the score. Future improvements in operational efficiency and financial stability are crucial.

Positive Factors

Financial Guidance

AGL raised the low end of its revenue guidance by $25MM to reflect retroactive membership assignment and corresponding revenue recognized in Q1.

Financial Performance

Revenue and adjusted EBITDA came in ahead of expectations despite updates from peers that cast doubt on AGL's business model.

Technological Advancements

AGL has made progress enhancing its platform and technology to drive improved visibility into revenues and claims.

Negative Factors

Persistent Issues

Results included material net negative PYD, which has been a persistent issue for AGL over the past couple of years.

Price Target Reduction

The price target was reduced from $6 to $4.

Uncertainty

There is still difficulty in gauging how improvement efforts will impact full year results, furthered by lack of clarity around risk profile mix in Class of 2025 and 2026 cohorts heading into FY26.

Agilon Health Business Overview & Revenue Model

Company Description

agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States. As of December 31, 2021, it served approximately 238,000 senior members, which included 186,300 medicare advantage members and 51,700 medicare fee-for-service beneficiaries. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. agilon health, inc. was founded in 2016 and is based in Austin, Texas.

How the Company Makes Money

Agilon Health generates revenue primarily through partnerships with physician groups by helping them transition to value-based care models. The company earns money by entering into long-term partnerships where it shares in the savings generated from improved patient outcomes and reduced healthcare costs. Agilon Health provides its partner physician groups with a comprehensive platform that includes technology, data analytics, and management services, which helps these groups manage patient care more efficiently. The company's revenue streams are largely driven by the shared savings and performance-based payments from payers, including Medicare Advantage plans. Significant partnerships with healthcare providers and insurers play a crucial role in its revenue generation strategy.

Agilon Health Financial Statement Overview

Summary

Agilon Health faces significant financial challenges with ongoing losses and negative cash flow. Despite strong revenue growth, profitability is lacking, impacting equity and cash positions. Low leverage offers some financial flexibility.

Income Statement

Agilon Health's income statement reveals significant challenges with profitability and growth. The TTM shows a gross profit margin of -0.53%, indicating costs exceed revenues. The net profit margin is -4.04%, reflecting ongoing losses. Revenue growth has been robust historically, with a compound annual growth rate of approximately 32% from 2020 to 2025 TTM, yet profitability remains elusive with negative EBIT and EBITDA margins in the TTM.

Balance Sheet

The balance sheet shows a moderate financial position. The debt-to-equity ratio of 0.08 in the TTM suggests low leverage, which is positive. However, the return on equity is negative due to consistent net losses, and the equity ratio has decreased from 66% in 2021 to 26% in the TTM, indicating growing liabilities and reduced equity.

Cash Flow

The cash flow analysis indicates weak cash generation. The operating cash flow to net income ratio is positive, suggesting some ability to convert income into cash, but free cash flow remains negative and volatile. The free cash flow to net income ratio shows a consistent pattern of cash outflows exceeding net income losses, reflecting ongoing cash challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	5.99B	6.06B	4.32B	2.71B	1.83B	1.22B
Gross Profit	-31.93M	4.84M	69.67M	112.29M	76.41M	94.15M
EBITDA	-214.40M	-218.19M	-167.64M	-72.41M	-383.78M	-40.11M
Net Income	-241.97M	-260.10M	-262.60M	-106.86M	-405.48M	-63.21M
Balance Sheet
Total Assets	1.93B	1.73B	1.74B	1.70B	1.59B	446.36M
Cash, Cash Equivalents and Short-Term Investments	367.08M	399.97M	488.34M	908.97M	1.04B	106.80M
Total Debt	42.02M	41.50M	52.31M	43.48M	48.40M	73.21M
Total Liabilities	1.43B	1.26B	1.08B	656.86M	494.66M	731.09M
Stockholders Equity	500.25M	470.95M	661.84M	1.04B	1.09B	-284.73M
Cash Flow
Free Cash Flow	-60.70M	-71.03M	-187.01M	-163.47M	-161.59M	-55.55M
Operating Cash Flow	-41.99M	-57.78M	-156.20M	-130.81M	-148.16M	-53.20M
Investing Cash Flow	65.36M	139.89M	-44.02M	-444.39M	-90.51M	22.07M
Financing Cash Flow	-3.30M	-2.58M	-193.13M	28.06M	1.15B	24.62M

Agilon Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.31
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AGL, the sentiment is Neutral. The current price of 2.31 is above the 20-day moving average (MA) of 2.21, below the 50-day MA of 2.86, and below the 200-day MA of 3.07, indicating a neutral trend. The MACD of -0.15 indicates Negative momentum. The RSI at 46.06 is Neutral, neither overbought nor oversold. The STOCH value of 77.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AGL.

Agilon Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ASTH	70 Outperform	$1.23B	34.10	5.00%	―	54.81%	-45.07%
SEM	64 Neutral	$1.96B	11.36	10.38%	1.67%	-8.86%	-36.22%
SGRY	61 Neutral	$2.81B	―	-10.43%	―	13.54%	-30732.00%
ACHC	60 Neutral	$1.93B	10.83	6.35%	―	5.48%	―
Sector *	54 Neutral	€4.82B	18.16	-49.50%	1.84%	13.92%	-2.48%
LFST	50 Neutral	$2.00B	―	-2.47%	―	16.31%	79.86%
AGL	44 Neutral	$902.41M	―	-42.95%	―	19.18%	-6.14%

Agilon Health Corporate Events

Agilon Health Elects New Directors at Annual Meeting

On May 28, 2025, Agilon Health held its annual meeting of stockholders where Silvana Battaglia and Sharad Mansukani, M.D. were elected as Class I directors to serve until the 2028 annual meeting. Additionally, stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for 2025 and approved, on a non-binding basis, the executive compensation for the company’s named officers.

The most recent analyst rating on (AGL) stock is a Sell with a $2.40 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.

Agilon Health Reports Q1 2025 Financial Results

On May 6, 2025, Agilon Health reported its financial results for the first quarter ending March 31, 2025, with total revenues of $1.53 billion, a 4% decrease from the previous year. The company experienced a decrease in total members on its platform to 605,000, reflecting market exits, but maintained its strategic growth priorities through investments in technology and clinical programs to enhance value for stakeholders.